STL Index for: Apremilast

Selective TYK2 Inhibition in the Treatment of Moderate to Severe Chronic Plaque Psoriasis

Moderate to severe chronic plaque psoriasis may be difficult to control using current therapies, which has led to development of a novel class of therapy, selective tyrosine kinase 2 (TYK2) inhibitors, to address this unmet need.

CaSMO Management of Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: A Practical Primer

The management of cirAEs starts with physician awareness and patient education on the occurrence of toxicities, preventive measures, and skincare using gentle cleansers, moisturizers, and sunscreen started before immunotherapy begins and ongoing thereafter as part of the lifestyle.

Janus Kinase and Tyrosine Kinase Inhibitors in Dermatology: A Review of Their Utilization, Safety Profile and Future Applications

Currently, JAK inhibitors are only FDA approved for dermatologic, rheumatologic, and hematologic conditions. Recent studies show the utility of JAK inhibitors in treating atopic dermatitis, psoriasis, psoriatic arthritis, vitiligo, and alopecia areata.

Update on Drugs & Devices: January-February 2022

Drug update covering: Adalimumab-adbm for SC use - Cyltezo®, Tralokinumab for SC use - Adtralza® (in Canada), Tralokinumab-ldrm for SC use - Adbry™ (in US), Melanoma vaccine for IV use - BNT111, Adalimumab-aqvh for SC use - Yusimry™, and more...

Psoriasis Education Tool for Patient-Physician Decision-Making About Biologics: A Pilot Study

Although biologics are well-studied, expertise regarding their use is often lacking. Many biologics have been added to the market in recent years with distinctive characteristics. This study was designed to create a tool to assist physicians involved in the care of patients with psoriasis undergoing biologic treatment.

Skin Treatments Introduced in 2019

A variety of new skin treatments introduced in 2019.

Apremilast in the Treatment of Psoriasis and Psoriatic Arthritis (Family Practice)

Phosphodiesterase 4 (PDE4) is a key enzyme in the regulation of immune responses of inflammatory diseases through degradation of the second messenger, cyclic adenosine 3',5'-monophosphate (cAMP). Apremilast (APR), a selective PDE4 inhibitor, has been shown to reduce the production of pro-inflammatory cytokines.

Apremilast in the Treatment of Psoriasis and Psoriatic Arthritis

Apremilast, a selective PDE4 inhibitor, has been shown to reduce the production of pro-inflammatory cytokines. A review of clinical trial data treating psoriasis, considering adverse effects, efficacy and tolerance.

Update on Drugs and Drug News: July-August 2015

Update on Deoxycholic acid injection (Kybella™), Ivermectin 1% cream (Rosiver®), Adalimumab SC injection (Humira®), Apremilast tablets (Otezla®), and Dermal filler with calcium hydroxylapatite (CaHA) (Radiesse®)

Current Management of Scalp Psoriasis

The scalp is involved in up to 80% of individuals with psoriasis. Topical treatment with corticosteroids with or without vitamin D3 analogues is the mainstay of treatment, but other therapies such as light treatment and systemic drugs including biologics are discussed.

Skin Treatments Introduced in 2014

An overview and update of skin treatments introduced in 2014: Quick overview of drug name, indications and regulatory status. Clindamycin phosphate 1.2% + benzoyl peroxide 3.75% gel (Onexton™), Doxycycline hyclate tablets (Acticlate™), Tretinoin gel microsphere 0.08% (Retin-A Micro®) and many other drugs are covered.

Update on Drugs and Drug News: January-February 2015

Update on Apremilast tablets (Otezla®), Collagenase clostridium histolyticum for injection (Xiaflex®), Afamelanotide 16 mg subcutaneous bioresorbable implants (Scenesse®), Clindamycin phosphate 1.2% + benzoyl peroxide 3.75% gel (Onexton™), Dupilumab SC injection, Apremilast tablets (Otezla®).

Update on Drugs and Drug News: May-June 2014

Update on Brimonidine tartrate 0.33% topical gel (Onreltea®Mirvaso®), Apremilast tablets (Otezla®), Miltefosine capsules (Impavido®), Hydrogel wound dressing (Loutrex®), Omalizumab for SC injection (Xolair®), Propranolol hydrochloride oral solution (Hemangeol™), Microbicide-coated condom Vivagel® (SPL7013 gel)

Small Molecules: An Overview of Emerging Therapeutic Options in the Treatment of Psoriasis

While biologics changed the way psoriasis is treated by providing effective targeted therapy, they are not without limitations. Small molecules are emerging therapeutic options for the treatment of psoriasis.

Update on Drugs and Drug News: March-April 2013

Update on Ingenol mebutate gel (0.015%, 0.05%) Picato™, Adapalene 0.1% + benzoyl peroxide 2.5% gel (Epiduo®), and Hydrogel for skin and wound care (Vashe® Skin and Wound Hydrogel)

Update on Drugs and Drug News: October 2012

Update on drugs, approval dates, and comments. Delayed-release prednisone tablets (Rayos®), Imiquimod 3.75% cream (Zyclara®), Lidocaine topical 5% patch, Clobetasol propionate 0.05% shampoo are covered.

Update on Drugs and Drug News – March 2008

Update on Anti-psoriatic Agent Adalimumab (Humira®), Antihistamine (Claritin®), HIV drug Etravirine (Intelence™) and news about new antioxidant, coffeeberry (REVALÉSKIN™, Stiefel Laboratories)

POPULAR

Advertisement